张志荣, 魏振平, 王莉, 廖方义. 米托蒽醌肝动脉栓塞羧甲基淀粉微球的研究J. 药学学报, 1998, 33(10): 772-777.
引用本文: 张志荣, 魏振平, 王莉, 廖方义. 米托蒽醌肝动脉栓塞羧甲基淀粉微球的研究J. 药学学报, 1998, 33(10): 772-777.
Zhang Zhirong, Wei Zhenping, Wang Li , Liao Fangyi, . STUDY ON THE MITOXANTRONE CARBOXYMETHYL STARCH MICROSPHERES FOR HEPATIC ARTERY CHEMOEMBOLIZATIONJ. Acta Pharmaceutica Sinica, 1998, 33(10): 772-777.
Citation: Zhang Zhirong, Wei Zhenping, Wang Li , Liao Fangyi, . STUDY ON THE MITOXANTRONE CARBOXYMETHYL STARCH MICROSPHERES FOR HEPATIC ARTERY CHEMOEMBOLIZATIONJ. Acta Pharmaceutica Sinica, 1998, 33(10): 772-777.

米托蒽醌肝动脉栓塞羧甲基淀粉微球的研究

STUDY ON THE MITOXANTRONE CARBOXYMETHYL STARCH MICROSPHERES FOR HEPATIC ARTERY CHEMOEMBOLIZATION

  • 摘要: 为进一步研究栓塞微球的制备工艺、体外释药规律及药动学与药效学之间的关系,以米托蒽醌为模型药物、羧甲基淀粉钠为载体材料、对苯二甲酰氯为交联剂,经均匀设计法优化了制备空白羧甲基淀粉微球的工艺,用吸附法制备了米托蒽醌载药羧甲基淀粉微球。对载药微球的理化性质进行了研究。并以家兔为模型动物研究了载药微球经肝动脉栓塞给药后的药代动力学情况。结果表明:载药微球的平均算术粒径为75.71μm,含药量为13.21%,吸水膨胀率为71.94%,体外释药符合单指数模型。药动学研究表明,米托蒽醌制成微球经肝动脉栓塞给药后可延长药物驻留于靶位的时间,提示有利于肝癌的治疗。

     

    Abstract: In this paper, the technology for the preparation of plain carboxymethyl starch microsphere (CMS-MS) was optimized by the uniform design method with CMS-Na as carrier material and p-phthaloyl chloride as acrosslinker. The carboxymethyl starch microsphere loaded mitoxantrone (DHAQ-CMS-MS) was prepared by absorption method. Then, its morphology, size and size distribution, characteristics of drug loading, drug release in vitro, preparation for clinical application and its stability were studied. The pharmacokinetics of DHAQ-CMS-MS in rabbit was also studied.The results showed that the average diameter of the DHAQ-CMS-MS was 75.71μm, drug loading was 13.21%, expansion ratio in water was 71.94%. The release of DHAQ in vitro from the microspheres was found to fit the model of single exponential function. The suspension prepared in this paper is not only convenient for clinical use, but also favorable for the improvement of the drug stability. The pharmacokinetic parameters obtained from the hepatic atery chemoembolization showed that the DHAQ-CMS-MS group, when compared with the solution group, exhibited a higher blood drug concentration in hepatic vein, its MRT was 1.96 times that of the solution group. As for the result of the peripheral vein, the MRT of the DHAQ-CMS-MS group was 1.95 times that of the solution group. This means that the drug when loaded in microsphere will be concentrated in its targeted site for a longer period, which is favorable for the treatment of hepatic cancer.

     

/

返回文章
返回